MEG
CRSP icon

Millstone Evans Group’s CRISPR Therapeutics CRSP Stock Holding History

Millstone Evans Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.2K Sell
22
-191
-90% -$10.1K ﹤0.01% 808
2026
Q1 		$10.1K Buy
213
+63
+42% +$3.32K 0.01% 571
2025
Q4 		$7.87K Buy
150
+75
+100% +$4.49K ﹤0.01% 581
2025
Q3 		$4.86K Hold
75
– – ﹤0.01% 636
2025
Q2 		$3.65K Buy
+75
New +$2.9K ﹤0.01% 618

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Millstone Evans Group's CRSP Position: Q2 2026 in Review

Millstone Evans Group reduced its CRISPR Therapeutics (CRSP) stake by 90% in Q2 2026, selling an estimated $10.1K and leaving 22 shares worth $1.2K. The position accounts for ﹤0.01% of the portfolio, ranked #808.

Millstone Evans Group first reported a position in CRSP in Q2 2025 and has held it in 5 quarters since. The position peaked at $10.1K in Q1 2026. 407 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Millstone Evans Group held 22 shares of CRISPR Therapeutics worth $1.2K as of Q2 2026.
  • Millstone Evans Group sold 191 CRISPR Therapeutics shares in Q2 2026, an estimated $10.1K.
  • CRISPR Therapeutics made up ﹤0.01% of Millstone Evans Group's portfolio in Q2 2026, its #808 holding.
  • Millstone Evans Group first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Millstone Evans Group's CRISPR Therapeutics position peaked at $10.1K in Q1 2026.
  • 407 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Millstone Evans Group's 13F filing for Q2 2026, filed 11 Aug 2026.